A moderate, but stable, depletion of CD4 + T cells was observed in MS patients treated with Mavenclad® tablets four or six months after the first treatment course, with a nadir of 50 % reduction from baseline (Stuve et al. 2019). The gene discussed is CD4; the disease is myeloid sarcoma.